Autocrine control of vitamin D metabolism in synovial cells from arthritic patients

Susan J Smith, Michael E Hayes, Peter L Selby, E Barbara Mawer

Abstract

Objective—This study was designed to investigate whether 1,25-dihydroxyvitamin D₃ (1,25-(OH)₂D₃), produced by activated synovial fluid macrophages, promotes its own catabolism by upregulating vitamin D-24-hydroxylase (24-OHase) in synovial fibroblasts through a vitamin D receptor (VDR) mediated mechanism.

Methods—Synovial macrophages and fibroblasts were derived from patients with rheumatoid arthritis. Expression of VDR and 24-OHase mRNAs was determined using in situ hybridisation. Vitamin D hydroxylase activity was determined by incubating cells with [³H]-25-(OH)D₃, or [³H]-1,25-(OH)₂D₃, and metabolite synthesis quantified using high performance liquid chromatography.

Results—1,25-(OH)₂D₃ increased expression of mRNA for both VDR and 24-OHase in fibroblasts by approximately threefold over 24 hours. 1,25-(OH)₂D₃ increased fibroblast 24-OHase activity, yielding 24-hydroxylated, and more polar, metabolites. In co-culture, fibroblasts were able to catabolise macrophage-derived 1,25-(OH)₂D₃.

Conclusions—1,25-(OH)₂D₃ is produced by macrophages in vitro at biologically relevant concentrations and can increase its own catabolism by synovial fibroblasts; this effect is probably mediated via up-regulation of both synovial fibroblast VDR and 24-OHase.


The active metabolite of vitamin D₃, 1α,25-dihydroxyvitamin D₃ (1,25-(OH)₂D₃), has immunoregulatory, pro-differentiating, and antiproliferative properties that have been shown to inhibit the progression of a number of autoimmune diseases, including experimental autoimmune encephalomyelitis and autoimmune diabetes. A recent paper by Cantorna et al. has shown that 1,25-(OH)₂D₃ can both prevent the development and halt the progression of arthritis in murine models of the human disease. Oral 1,25-(OH)₂D₃ treatment has also been shown to improve human psoriatic arthritis, and its analogue 1α-hydroxyvitamin D₃ inhibits type II collagen induced arthritis in rats.

Exogenous administration of 1,25-(OH)₂D₃ may be a useful therapeutic approach for arthritis, however substrate dependent endogenous production of 1,25-(OH)₂D₃ can occur within the arthritic joint in vivo. The source of the extra-renal 1,25-(OH)₂D₃ is likely to be the synovial macrophage, as we have demonstrated in vitro that macrophages isolated from the synovial fluids of patients with inflammatory arthritis express vitamin-D-1α-hydroxylase (1-OHase) activity, which can be regulated by locally encountered factors such as cytokines, for example, interferon gamma (IFNγ), bacterial lipopolysaccharide, and eicosanoids.

Another vitamin D hydroxylase enzyme, namely the 24-hydroxylase (24-OHase), is responsible for the catabolism of 1,25-(OH)₂D₃, and is expressed by synovial fibroblasts. 1,25-(OH)₂D₃ and its receptor (VDR) bind to the vitamin D response elements (VDRs) of target genes to control their transcription and, as the promoter region of the human 24-OHase gene contains VDRs, it appears that the activity of the synovial fibroblast 24-OHase might be under the control of the local concentration of macrophage-derived 1,25-(OH)₂D₃. In this study we wanted to investigate how induction of synovial fibroblast 24-OHase by 1,25-(OH)₂D₃, may, in turn, regulate the local concentration of 1,25-(OH)₂D₃ in the synovial joint. In theory, this could be done via several mechanisms. Firstly, it may promote catabolism of existing 1,25-(OH)₂D₃ to 1,24,25-(OH)₃D₃, the start of the catabolic cascade for 1,25-(OH)₂D₃. While 1,24,25-(OH)₃D₃ has some biological activity, it is less potent than the precursor 1,25-(OH)₂D₃. Secondly, the 24-OHase may lessen the pool of precursor 25-(OH)D₃ available to macrophages for 1-hydroxylation (which is known to be substrate dependent), by diverting 25-(OH)D₃ into the synthesis of 24,25-dihydroxyvitamin D₃ (24,25-(OH)₂D₃). An increase in 24,25-(OH)₂D₃ concentration may itself provide a third mechanism to reduce entry of freshly synthesised 1,25-(OH)₂D₃ into the system; we have demonstrated that 24,25-(OH)₂D₃ can be converted to 1,24,25-(OH)₃D₃ by synovial fluid macrophages (unpublished data), and will therefore compete with 25-(OH)D₃ as a substrate for 1-hydroxylation.

If 1,25-(OH)₂D₃ (or one of its analogues) is to be used therapeutically for inflammatory arthropathies it is important to understand its breakdown in vivo, firstly for the administration of an effective dose and secondly to ensure that the concentration of 1,25-(OH)₂D₃ can be controlled locally, thus preventing unwanted systemic side effects and possible juxtaarticular osteoporosis. The aim of this study was to investigate further the regulation of the
synovial fibroblast 24-OHase by 1,25-(OH)₂D₃ in vitro, at both the molecular and functional level, and to determine whether this effect is mediated via VDR. Expression of synovial fibroblast VDR and 24-OHase mRNAs was determined using in situ hybridisation. The effects of exposure to 1,25-(OH)₂D₃ on the metabolism of [TH]-25-(OH)₂D₃ and [TH]-1,25-(OH)₂D₃, by synovial fibroblasts, and the effects of fibroblasts on the metabolism of 1,25-(OH)₂D₃ produced by macrophages when the two cell types were co-cultured, were also investigated using a hydroxylase assay.

Methods

SOURCE OF SYNOVIAL CELLS

Synovial fibroblasts (designated F733), derived from an explant culture from a patient with rheumatoid arthritis, were kindly supplied by Dr David Taylor. Cells were routinely grown in Dulbecco’s modified Eagle's medium (DMEM) containing 1 × 10⁻³ M sodium pyruvate (Gibco), 2 × 10⁻³ M L-glutamine, 50 IU/ml penicillin, 50 µg/ml streptomycin, and 10% v/v fetal bovine serum (Imperial) and passaged 1–2 weeks using 0.25% trypsin, 0.02% w/v EDTA in phosphate buffered saline (Imperial). Cells were used at passage 10 in these experiments.

A primary culture of synovial fluid macrophages was established from the synovial fluid of a patient with rheumatoid arthritis using the method of Hayes et al.12 Briefly, the synovial fluid sample was diluted in RPMI-1640 culture medium containing 2% v/v fetal bovine serum, 4 × 10⁻³ M L-glutamine, 10 IU/ml penicillin, and 10 µg/ml streptomycin. From experience, we have found that incubating the sample in 2% v/v fetal bovine serum, rather than 10% v/v fetal bovine serum, encourages the culture of macrophages, but not fibroblasts, thus allowing fibroblast free cultures of macrophages to be established. Any macrophage culture contaminated by fibroblasts can be readily identified, because fibroblasts proliferate in culture and can be seen as colonies.

The sample was incubated at 37°C in a humidified atmosphere of air with 5% carbon dioxide for 2–3 days; after this time macrophages had adhered to the culture plate surface and non-adherent cells were washed away. All cells from the sample stained positive for non-specific esterase activity, a marker of monocyte-macrophages.

DETERMINATION OF mRNA EXPRESSION USING IN SITU HYBRIDISATION

F733 cells were pre-treated for five or 24 hours with 5 × 10⁻⁸ M 1,25-(OH)₂D₃ (Hoffman La Roche) or vehicle (0.125% v/v ethanol) in glass chamber slides (Lab-Tek) and fixed in 10% v/v formaldehyde. Expression of VDR and 24-OHase mRNA was determined using in situ hybridisation with [³⁵S] labelled riboprobes. The 2.1 kb human VDR cDNA probe was kindly supplied by Dr G Williams already sub-cloned into the ampicillin resistant plasmid pBluescript II KS (Stratagene). The 1.8 kb partial length human 24-OHase cDNA probe was kindly supplied by Drs J Omdahl and B May, cloned into the Pst I site of Bluescript KS+. The in situ hybridisation technique used in this study has previously been described by Mee et al.17 Controls were sense riboprobe and RNAse A treated cells (Sigma; 1 mg/ml in water for one hour at 37°C) to ensure that probe binding to cells was RNA specific. Probe hybridisation was detected by dipping slides in photographic emulsion (Ilford K5) diluted 1:1 with distilled water and developed after seven days at 4°C. The radiation produces silver grains within the emulsion that can be visualised as “black dots” and, as the path length of [³⁵S] is 15–20 µm, the positions of the black dots localise the areas of probe binding. Cells were counterstained using eosin and Harris haematoxylin and examined using light field microscopy. Probe hybridisation was quantified with a Quantimet 600 image analyser linked to a Leica DM microscope (Leica UK Ltd), allowing the percentage cell area covered by silver grains to be calculated, corrected for background levels of probe binding.

DETERMINATION OF VITAMIN D HYDROXYLASE ACTIVITY

Effect of 1,25-(OH)₂D₃ on synovial fibroblast vitamin D hydroxylase activity

To study the effects of 1,25-(OH)₂D₃ on F733 vitamin D hydroxylase activity, cells were pre-treated with 1,25-(OH)₂D₃ (10⁻⁷ to 10⁻¹¹ M), or vehicle (ethanol, 0.25% v/v), in DMEM containing 6.25 µg/ml insulin, 6.25 µg/ml transferrin, 6.25 ng/ml selenious acid, 1.25 mg/ml bovine serum albumin (BSA), 5.35 µg/ml linoleic acid (ITS’; Becton Dickinson), 2 × 10⁻³ M L-glutamine, 50 IU/ml penicillin, and 50 µg/ml streptomycin. Cells were incubated for 24 hours in a humidified atmosphere of 95% air, 5% carbon dioxide, then washed and left for three hours in ITS’ supplemented DMEM; this allowed time for any pre-treatment 1,25-(OH)₂D₃ to be metabolised by cells before incubation with substrate. Enzyme activity was then determined by incubating cells for 1.5 hours in fresh DMEM containing either 25-(OH)₂D₃, or 1,25-(OH)₂D₃ (358 pg/ml and 43.5 pg/ml respectively), supplemented with 5 × 10⁻⁴ dpm tritiated substrate (25-hydroxy [26,27-methyl-³H] cholecalciferol ([³H]-25-(OH)₂D₃), specific activity about 15.0 Ci/mmol or 1α,25-dihydroxy [26,27-methyl-³H] cholecalciferol ([³H]-1,25-(OH)₂D₃), specific activity about 173 Ci/mmol; Amersham) 0.5% v/v BSA (Orthodiagnostic Systems Ltd) and 2 × 10⁻³ M L-glutamine, using the hydroxylase assay described previously by Hayes et al.5 A blank incubation (no cells) was also included in the assay. Metabolites were extracted using chloroform: methanol, 3:2 v/v and quantified using high performance liquid chromatography (HPLC) and liquid scintillation counting. Briefly, the chloroform layer was extracted and analysed on a manual injection normal phase HPLC system developed with a mobile phase of n-hexane:isopropanol:methanol, 115:3:5:4 (v/v). A Zorbax-Sil column (4.6 mm × 25 cm). Eluant fractions were collected, the radioactivity measured, and the...
known specific activity of substrate used to calculate the rate of synthesis of vitamin D$_3$ metabolites in each sample. An aliquot of the upper aqueous phase of the extraction mixture was also counted as a measure of more polar metabolites.

**Synovial macrophages and fibroblasts in co-culture**

A co-culture system was established to determine whether synovial macrophage derived 1,25-(OH)$_2$D$_3$ could be directly 24-hydroxylated by F733 in vitro to form 1,24,25-(OH)$_3$D$_3$. F733 were grown in sterile 12 mm diameter polystyrene well inserts (Costar), which could fit into the wells of a 12 well tissue culture dish (Corning) in which the macrophages were cultured. The inserts had a 3.0 µm porous membrane that allowed the culture medium to move freely between the chambers. Adequate synthesis of 1,25-(OH)$_2$D$_3$ by macrophages was ensured by pre-treatment for 24 hours with 5 × 10^{-9} M interferon gamma (IFN$_\gamma$; Advanced Protein Products Ltd). After

![Figure 1 Photomicrographs showing hybridisation of $[^{35}$S] labelled riboprobe for 24-OHase and VDR mRNAs in F733 synovial fibroblasts. F733 cells were pre-treated with 5 × 10^{-9} M 1,25-(OH)$_2$D$_3$ or vehicle (0.125% v/v ethanol), fixed, then hybridised overnight with $[^{35}$S] labelled riboprobe for 24-OHase or VDR mRNA. (A) Twenty four hour vehicle treated cells, 24-OHase probe; (B) 24 hour 1,25-(OH)$_2$D$_3$ treated cells, 24-OHase probe; (C) RNase A treated control slide, 24-OHase probe; (D) 24 hour vehicle treated cells, VDR probe; (E) 24 hour 1,25-(OH)$_2$D$_3$ treated cells, VDR probe; (F) RNase A treated control slide, VDR probe. Bar = 50 µm, cells counterstained with eosin and Harris haematoxylin (Sigma).
pre-treatment, macrophages were washed once with basal medium, then incubated alone or in combination with F733 for a further 24 hours with [3H]-25-(OH)D₃ (12.5 ng/ml) using the hydroxylase assay described above.

STATISTICS
Statistical analysis of results was carried out with Instat for Macintosh (version 2.01), using analysis of variance (ANOVA) and Student’s t test. Non-normally distributed data were log transformed before analysis.

Results
REGULATION OF 24-0HASE AND VDR mRNAs BY 1,25-(OH)₂D₃ IN F733 SYNOVIAL FIBROBLASTS
24-OHase mRNA (fig 1 (A–C))
Pre-treatment with 1,25-(OH)₂D₃ for either five or 24 hours increased probe binding to F733, indicating an increase in 24-OHase mRNA. At both time points some cells had very high activity while others had very low activity, possibly because of differences in the state of cell differentiation or cell cycle, or both. The extent of hybridisation was quantified and expressed as the % cell area covered by silver grains. There was a significant increase in probe binding (p < 0.01) from 2.3 (0.5)% (mean (SEM)) in cells treated with vehicle for five hours to 6.2 (1.0)% in cells treated with 1,25-(OH)₂D₃ for five hours (results not shown). There was a similar increase in probe binding (p < 0.05) from 1.7 (0.3)% in cells treated with vehicle for 24 hours (fig 1(A)) to 5.1 (2.2)% in cells treated with 1,25-(OH)₂D₃ for 24 hours (fig 1(B)). Both RNase A treated control slides (fig 1(C)) and sense riboprobe control slides showed only background levels of silver grains.

VDR mRNA (fig 1 (D–F))
There was an increase in probe binding to F733 cells after 24 hours of 5 × 10⁻⁸ M 1,25-(OH)₂D₃ treatment, but not after five hours. Percentage silver grain density for five hour vehicle, five hour 1,25-(OH)₂D₃ treated cells, and 24 hour vehicle were 1.4 (0.2)%, 1.5 (0.3)%, and 1.5 (0.2)% respectively. Binding after 24 hour 1,25-(OH)₂D₃ pre-treatment (4.5 (0.5)%; fig 1(E)) was significantly increased compared with the 24 hour vehicle (fig 1(D); p < 0.01) and five hour treatment values (p < 0.01). Again, both RNase A treated control slides (fig 1(F)) and sense riboprobe control slides showed only background levels of silver grains.

Expression of Vitamin D Hydroxylase Activity (from Hydroxylase Assays)
Metabolism of [3H]-25-(OH)D₃ by synovial fibroblasts pre-treated with 1,25-(OH)₂D₃
The HPLC trace in fig 2(A) shows the typical metabolism of [3H]-25-(OH)D₃ (peak A) to [3H]-24,25-(OH)₂D₃ (peak B) and an unidentified metabolite (peak D). The solid trace in figure 2 (B) shows the metabolism of substrate [3H]-25-(OH)D₃ by synovial fluid fibroblasts pre-treated for 24 hours with 10⁻⁸ M 1,25-(OH)₂D₃ for five or 24 hours increased probe binding to F733, indicating an increase in 24-OHase mRNA. The extent of hybridisation was quantified and expressed as the % cell area covered by silver grains. There was a significant increase in probe binding (p < 0.01) from 2.3 (0.5)% (mean (SEM)) in cells treated with vehicle for five hours to 6.2 (1.0)% in cells treated with 1,25-(OH)₂D₃ for five hours (results not shown). There was a similar increase in probe binding (p < 0.05) from 1.7 (0.3)% in cells treated with vehicle for 24 hours (fig 1(A)) to 5.1 (2.2)% in cells treated with 1,25-(OH)₂D₃ for 24 hours (fig 1(B)). Both RNase A treated control slides (fig 1(C)) and sense riboprobe control slides showed only background levels of silver grains.

Expression of Vitamin D Hydroxylase Activity (from Hydroxylase Assays)
Metabolism of [3H]-25-(OH)D₃ by synovial fibroblasts pre-treated with 1,25-(OH)₂D₃
The HPLC trace in fig 2(A) shows the typical metabolism of [3H]-25-(OH)D₃ (peak A) to [3H]-24,25-(OH)₂D₃ (peak B) and an unidentified metabolite (peak D) by F733 cells pre-treated for 24 hours with 10⁻⁸ M 1,25-(OH)₂D₃. Fig 3 (A) shows that synthesis of [3H]-24,25-(OH)₂D₃, was increased in a dose dependent manner by increasing pre-treatment concentrations of 1,25-(OH)₂D₃ with a mean
SEM of 73.8 (5.3) fmol/h/10^6 cells in controls (vehicle treated), and maximum activity of 463.1 (14.6) fmol/h/10^6 cells in 10^{-8} M pre-treated cells (p < 0.01). The unidentified metabolite (peak D in figures 2(A), and 3 (B)), which was more polar than 24,25-(OH)_{2}D_{3}, was also synthesised in a dose dependent manner, and was not present in blank (no cells) samples, indicating this is a metabolite and not an incubation artefact. This metabolite was not 25,26-dihydroxyvitamin D_{3}, which elutes between 24,25-(OH)_{2}D_{3} and 1,25-(OH)_{2}D_{3} in our solvent system.

An aliquot of the aqueous phase was added to scintillation cocktail and [3H] dpm measured. The unidentified radioactivity present in the aqueous phase (corrected from the blank (no cells) incubation) increased with 1,25-(OH)_{2}D_{3} pre-treatment concentration (fig 3 (C)). This radioactivity indicates the presence of more polar products than those found in the chloro-

Figure 3  Effects of 1,25-(OH)_{2}D_{3} pre-treatment on the metabolism of [3H]-25-(OH)_{3}D_{3} and [3H]-1,25-(OH)_{2}D_{3} by F733 synovial fibroblasts. Panels (A–C) are cells incubated with [3H]-25-(OH)_{3}D_{3} substrate, panels (D–F) are cells incubated with [3H]-1,25-(OH)_{2}D_{3} substrate. (A) Synthesis of [3H]-24,25-(OH)_{2}D_{3}; (B) synthesis of an unidentified product (peak D in fig 2(A)); (C) the radioactivity present in the aqueous phase; (D) synthesis of [3H]-1,24,25-(OH)_{3}D_{3}; (E) synthesis of an unidentified product (peak F in figure 2(B)) and (F) radioactivity present in the aqueous phase. n=3 for each point. Results are shown as mean (SEM). *p<0.05, **p<0.01 compared with vehicle (0.25% ethanol) using ANOVA followed by Dunnett’s multiple comparison test.
Table 1 Metabolism of [3H]-25-(OH)D3 by synovial fibroblasts and macrophages incubated separately and in co-culture

<table>
<thead>
<tr>
<th>Metabolite synthesis (pmol/incubation/24 h)</th>
<th>Macrophages (untreated)</th>
<th>IFNγ pre-treated macrophages</th>
<th>F733 (untreated)</th>
<th>Co-culture</th>
</tr>
</thead>
<tbody>
<tr>
<td>24,25-(OH)D₃</td>
<td>nd</td>
<td>nd</td>
<td>10.9 (0.8)</td>
<td>7.4 (0.2)</td>
</tr>
<tr>
<td>1,25-(OH)D₃</td>
<td>12.1 (4.6)</td>
<td>34.6 (3.0)</td>
<td>nd</td>
<td>12.4 (0.3)</td>
</tr>
<tr>
<td>1,24,25-(OH)₃</td>
<td>nd</td>
<td>nd</td>
<td>6.7 (0.0)</td>
<td>6.7 (0.0)</td>
</tr>
</tbody>
</table>

Results are expressed as mean (SEM); n=3; nd=none detected. The co-culture incubation consisted of F733 (untreated) and IFNγ pre-treated macrophages.

form layer, however the number and nature of metabolites present in the aqueous phase was not determined.

Metabolism of [3H]-1,25-(OH)D₃ by synovial fibroblasts pre-treated with 1,25-(OH)D₃

The HPLC trace in figure 2 (B) shows the typical metabolism of [3H]-1,25-(OH)D₃, (peak C) to [3H]-1,24,25-(OH)₃D₃, (peak E) and an unidentified metabolite (peak F) by F733 pre-treated for 24 hours with 10⁻¹¹ M 1,25-(OH)D₃. As no radioactive tracer was available for 1,24,25-(OH)₃D₃, a non-ultraviolet absorbance trace of unlabelled 1,24,25-(OH)₃D₃ was used as a marker. 1,25-(OH)D₃ pre-treatment led to an increase in putative [3H]-1,24,25-(OH)₃D₃, synthesis (fig 3 (D)) with a mean (SEM) of 5.6 (0.9) fmol/h/10⁶ cells in vehicle treated control cells (0.25% v/v ethanol) to 33.3 (2.7) fmol/h/10⁶ cells in 10⁻⁸ M treated cells (p<0.01). The concentration of [3H]-1,24,25-(OH)₃D₃, peaked with 10⁻⁹ M 1,25-(OH)D₃ pre-treatment and declined at 10⁻⁸ M and 10⁻⁷ M. It is possible that the cells pre-treated with these higher concentrations of 1,25-(OH)D₃ had started to metabolise [3H]-1,24,25-(OH)₃D₃ to further catabolic products, which would explain the much higher peaks in the culture phase seen with these two treatment points (fig 3 (F)). 1,25-(OH)D₃ pre-treatment had no significant effect on the synthesis of the unidentified more polar metabolite (peak F in fig 2 (B), and fig 3 (E)).

Vitamin D metabolism in synovial macrophages and fibroblasts in co-culture

Table 1 shows the rates of [3H]-vitamin D₃ metabolite synthesis by synovial fluid macrophages and fibroblasts alone and in co-culture. F733 cells synthesised 24,25-(OH)D₃, while macrophages synthesised 1,25-(OH)D₃. IFNγ stimulated macrophages synthesised increased levels of 1,25-(OH)D₃, and a small quantity of putative 1,24,25-(OH)₃D₃—possibly because of induction of macrophage 24-OHase activity when local 1,25-(OH)D₃ levels were high. The co-culture of F733 and IFNγ stimulated macrophages showed synthesis of 1,25-(OH)D₃, 24,25-(OH)D₃, and 1,24,25-(OH)₃D₃. There were also increased concentrations of [3H] metabolites in the aqueous phases of the co-culture incubations than in cells incubated separately (p<0.001).

Discussion

We have demonstrated previously that 1,25-(OH)D₃ may be synthesised locally within the arthritic joint⁴ and have studied the regulation of synovial macrophage 1-Ohase activity in vitro. We have now extended these observations to show that, in vitro at least, fibroblasts of synovial origin can regulate the local 1,25-(OH)D₃ concentration at or near its site of synthesis. Moreover, this mechanism is regulated in a dose dependent fashion by 1,25-(OH)D₃ itself, acting in a paracrine mode, with a significant effect seen at near physiological concentrations (10⁻¹⁰ M). The stimulatory effects of 1,25-(OH)D₃ on synovial fibroblast 24-OHase activity may be sufficient to catabolise raised local 1,25-(OH)D₃ levels, however if supraphysiological concentrations of 1,25-(OH)D₃ persist, an increase in VDR mRNA and protein may be required to increase the clearance rate.

We have previously studied the effect of 1,25-(OH)D₃ on 24-OHase activity and mRNA in a variety of rheumatoid synovial fibroblast cell lines, and on the same lines at different passage numbers, and always found a stimulatory effect on both 24-hydroxylase and mRNA levels—so much so, that fibroblast cell lines were used as reliable positive controls in house for the in situ hybridisation method. We have not studied fibroblasts from osteoarthritic synovium, however it would be interesting to see if there were differences in the expression of these molecules in the different disease states, particularly as we have previously shown a difference in endogenous 1,25-(OH)D₃ synthesis in rheumatoid and osteoarthritis.²

Once the stimulatory effect of exogenous 1,25-(OH)D₃ on fibroblast 24-OHase had been established, we examined the metabolism of 25-(OH)D₃ by macrophages and fibroblasts in co-culture. We have now demonstrated that synovial fibroblasts can metabolise macrophase derived 1,25-(OH)D₃ to 1,24,25-(OH)₃D₃, and more polar metabolites in exactly the same way as exogenous 1,25-(OH)D₃, confirming the hypothesis that fibroblasts are able to regulate the concentration of locally synthesised 1,25-(OH)D₃ in vitro.

Our experiments also indicate that a relatively small number of macrophages (2.18×10⁶ cells per incubation) have the ability to make a large amount of 1,25-(OH)D₃. The concentration of substrate 25-(OH)D₃ used in the co-culture system was physiological (12.5 ng/ml or 3.125×10⁻⁸ M) and resulted in 1,25-(OH)D₃ concentrations of approximately 6×10⁻⁸ M and 1.7×10⁻⁹ M in control and IFNγ stimulated cultures respectively after 24 hours. As the normal serum concentration of 1,25-(OH)D₃ is in the order of 10⁻¹⁰ M to 10⁻¹¹ M (20–50 pg/ml; from Mawer et al)², it is theoretically possible that, unless regulated, high concentrations of 1,25-(OH)D₃ could be synthesised in the joint within a relatively short time period. The concentration of macrophase derived 1,25-(OH)D₃ was reduced to 6×10⁻⁸ M in the co-culture incubation (24 hour incubation).
bation with $2.18 \times 10^7$ macrophages and $1.1 \times 10^7$ fibroblasts), because of the catabolic effects of the fibroblast 24-OHase. This is one third of the concentration present in the IPNγ-stimulated macrophages alone, although the regulatory effect of the fibroblasts may depend on the ratio of the different cell types and incubation time. Macrophages and fibroblasts are generally the predominant cell types in the rheumatoid lesion, but their relative proportion and distribution can be highly variable, even within the same specimen. We have measured the synovial fluid concentration of 1,25-(OH)₂D₃ in patients with rheumatoid arthritis receiving oral vitamin D₃ treatment and shown that concentrations were up to $2.5 \times 10^{-10}$ M (100 pg/ml; unpublished results). We did not detect concentrations higher than this in vivo, possibly because of insufficient substrate, inactivated macrophages or local breakdown within the joint in analogous fashion to that which we described in the co-culture in vitro.

The beneficial effects of 1,25-(OH)₂D₃ in a number of animal models of autoimmunity, including experimental autoimmune encephalitis and autoimmune diabetes, have led to the suggestion that 1,25-(OH)₂D₃, or one of its analogues, may be a valuable treatment approach to arthritis. It would be possible, rather than giving 1,25-(OH)₂D₃, or its analogues, systematically (as was the case for the animal experiments), to inject it locally into the joint, as for corticosteroid treatment, thus targeting the site of inflammation directly. Our findings on the ability of 1,25-(OH)₂D₃ to stimulate its own catabolism within the environment of the synovial joint would be of critical importance in regulating the local concentration of 1,25-(OH)₂D₃ in these circumstances.

Funding: this work was supported by the Arthritis and Rheumatism Council for Research.

Autocrine control of vitamin D metabolism in synovial cells from arthritic patients

Susan J Smith, Michael E Hayes, Peter L Selby and E Barbara Mawer

doi: 10.1136/ard.58.6.372

Updated information and services can be found at:
http://ard.bmj.com/content/58/6/372

These include:

References

This article cites 19 articles, 7 of which you can access for free at:
http://ard.bmj.com/content/58/6/372#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

- Immunology (including allergy) (5144)
- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/